2024
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium
Han J, Koh M, Boussi L, Sorial M, McCabe S, Peng L, Singh S, Eche-Ugwu I, Gabler J, Fernandez Turizo M, MacVicar C, Garg A, Disciullo A, Chopra K, Lenart A, Nwodo E, Barnes J, Koh M, Miranda E, Chiattone C, Stuver R, Horwitz S, Merrill M, Jacobsen E, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim Y, Kim J, Cho J, Eipe T, Shet T, Epari S, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince H, Hamouche R, Muradashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al-Mansour M, Ford J, Cabrera M, Ku A, Bhagat G, Ma H, Sawas A, Kariya K, Iwasaki M, Bhanushali F, O'Connor O, Marchi E, Shen C, Shah D, Jain S. Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium. Blood Advances 2024 PMID: 39481087, DOI: 10.1182/bloodadvances.2024014674.Peer-Reviewed Original ResearchNK-cell lymphomasOverall survivalMature T cellsALK-ALCLNK cellsT cellsAssociated with 3-year OSTiming of second-line treatmentSuperior median overall survivalMedian overall survivalPrimary refractory diseaseProgression-free survivalInternational retrospective cohort studySecond-line treatmentEfficacy of novel drugsIdentified several independent predictorsRetrospective cohort studyR/R lymphomaExtranodal sitesPTCL-NOSIntermediate-riskCytotoxic chemotherapyHistological subtypesRefractory diseaseRelapsed lymphomaPhase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma
Witzig T, Sokol L, Kim W, de la Cruz Vicente F, García-Sancho A, Advani R, Vidal J, de Oña Navarrete R, Marin-Niebla A, Izquierdo A, Terol M, Domingo-Domenech E, Saunders A, Bendris N, Mackey J, Leoni M, Foss F. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma. Blood Advances 2024, 8: 4581-4592. PMID: 38991123, PMCID: PMC11401221, DOI: 10.1182/bloodadvances.2024012806.Peer-Reviewed Original ResearchRelapsed/refractory peripheral T-cell lymphomaAngioimmunoblastic T-cell lymphomaPeripheral T-cell lymphomaT-cell lymphomaProgression-free survivalDuration of responseAdverse eventsAngioimmunoblastic T-cell lymphoma patientsMedian duration of responseMedian progression-free survivalSafety of tipifarnibHematologic adverse eventsMedian overall survivalTreatment-related deathsBiomarkers of responsePhase 2 trialSixty-five patientsFarnesyltransferase inhibitor tipifarnibNon-responder groupTumor mutational profileSingle-arm trialPTCL-NOSOpen-labelOverall survivalPrimary endpoint
2021
Comparative Analysis of Mature T-Cell and NK/T-Cell Lymphomas in Patients with and without HIV: Results from the NA-Accord and Complete Cohorts
Koh M, Merrill M, Koh M, Stuver R, Alonso C, Foss F, Mayor A, Gill M, Epeldegui M, Cachay E, Thorne J, Silverberg M, Horberg M, Atlhoff K, Nijhawan A, McGinnis K, Rabkin C, Napravnik S, Shen C, Jain S. Comparative Analysis of Mature T-Cell and NK/T-Cell Lymphomas in Patients with and without HIV: Results from the NA-Accord and Complete Cohorts. Blood 2021, 138: 1380. DOI: 10.1182/blood-2021-147837.Peer-Reviewed Original ResearchNK/T-cell lymphomaT-cell lymphomaB-cell lymphomaNA-ACCORDViral loadBurkitt's lymphomaLymphoma diagnosisCurrent antiretroviral therapy eraWorse median overall survivalPeripheral T-cell lymphomaAnaplastic large cell lymphomaLarge B-cell lymphomaAntiretroviral therapy eraBaseline clinical characteristicsMedian overall survivalMulticenter cohort studyOutcomes of patientsSpeakers bureauChronic kidney diseasePrimary CNS lymphomaYear of diagnosisCommon histological subtypeMature T-cell lymphomasSurvival of patientsLarge observational cohort
2019
Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry
Stuver RN, Khan N, Schwartz M, Acosta M, Federico M, Gisselbrecht C, Horwitz SM, Lansigan F, Pinter‐Brown L, Pro B, Shustov AR, Foss FM, Jain S. Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry. American Journal Of Hematology 2019, 94: 641-649. PMID: 30896890, PMCID: PMC7928240, DOI: 10.1002/ajh.25463.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaRefractory peripheral T-cell lymphomaComprehensive Oncology MeasuresT-cell lymphomaCombination chemotherapyFirst retreatmentSingle agentCombination therapyR diseaseTreatment RegistryEligibility criteriaR Peripheral T Cell LymphomaHematopoietic stem cell transplantationPrior systemic therapyComplete response rateMedian overall survivalProgression-free survivalStem cell transplantationPrimary endpointAdverse eventsOverall survivalSystemic therapyMore patientsRandomized trialsGrade 3The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study
Park SI, Horwitz SM, Foss FM, Pinter‐Brown L, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Shustov AR, Investigators F. The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer 2019, 125: 1507-1517. PMID: 30694529, PMCID: PMC8269282, DOI: 10.1002/cncr.31861.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesFemaleHematopoietic Stem Cell TransplantationHumansImmunoblastic LymphadenopathyLymphatic MetastasisLymphoma, T-Cell, PeripheralMaleMiddle AgedRemission InductionRetrospective StudiesTransplantation, AutologousYoung AdultConceptsAutologous stem cell transplantationPeripheral T-cell lymphomaNodal peripheral T-cell lymphomaAngioimmunoblastic T-cell lymphomaT-cell lymphomaConsolidative autologous stem cell transplantationFirst complete remissionStem cell transplantationComplete remissionCohort studyCell transplantationImpact of ASCTAggressive peripheral T-cell lymphomaFirst large prospective cohort studyHigh International Prognostic Index scoreUntreated peripheral T-cell lymphomaAnaplastic lymphoma kinase-negative anaplastic large cell lymphomaInternational Prognostic Index scoreLarge prospective cohort studyAnaplastic large cell lymphomaComprehensive Oncology MeasuresMedian overall survivalMulticenter cohort studyAdvanced stage diseaseProgression-free survival
2018
Peripheral T cell lymphoma, not otherwise specified (PTCL‐NOS). A new prognostic model developed by the International T cell Project Network
Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, Pileri S, Ko Y, Cabrera ME, Horwitz S, Kim WS, Shustov A, Foss FM, Nagler A, Carson K, Pinter‐Brown L, Montoto S, Spina M, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Gabus R, Vose JM, Advani RH, Network T. Peripheral T cell lymphoma, not otherwise specified (PTCL‐NOS). A new prognostic model developed by the International T cell Project Network. British Journal Of Haematology 2018, 181: 760-769. PMID: 29672827, PMCID: PMC6033106, DOI: 10.1111/bjh.15258.Peer-Reviewed Original ResearchConceptsT-cell ProjectPeripheral T-cell lymphomaT cell scoreProgression-free survivalT-cell lymphomaOverall survivalCell lymphomaCells projectCox proportional hazards regression analysisMultiple Cox proportional hazards regression analysisProportional hazards regression analysisMedian overall survivalHazards regression analysisNew prognostic modelIntermediate riskPTCL-NOSPrognostic valueUnfavourable outcomeClinical variablesRetrospective analysisHigh riskLower riskPrognostic modelGood discriminant powerNew scoreThe outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project
Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko YH, Martinez V, Montoto S, Chiattone C, Moskowitz A, Spina M, Biasoli I, Manni M, Federico M. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica 2018, 103: 1191-1197. PMID: 29599200, PMCID: PMC6029527, DOI: 10.3324/haematol.2017.186577.Peer-Reviewed Original ResearchConceptsBone marrow transplantationInternational T-cell ProjectPeripheral T-cell lymphoma patientsT-cell lymphoma patientsT-cell ProjectOverall survivalMarrow transplantationLymphoma patientsRelapsed Peripheral T-Cell LymphomaPeripheral T-cell lymphomaUnivariate Cox regression analysisChemotherapy-sensitive diseaseMedian overall survivalFirst-line therapyFirst-line treatmentOverall survival rateSurvival of patientsCox regression analysisEnd of treatmentStandard of careT-cell lymphomaMedian followPrimary refractoryBetter OSRefractory/
2015
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model
Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal Of Clinical Oncology 2015, 33: 3766-3773. PMID: 26438120, PMCID: PMC4979132, DOI: 10.1200/jco.2015.61.7142.Peer-Reviewed Original ResearchConceptsMF/Sézary syndromeAdvanced-stage MF/Sézary syndromeMedian overall survivalSézary syndromeIndependent prognostic markerOverall survivalPrognostic markerWorse survivalMycosis fungoidesAdvanced MF/SSSurvival rateAdvanced-stage mycosis fungoidesIdentical T-cell clonesStage IIB diseaseStage III diseaseStage IV diseaseSingle-center trialAdvanced-stage patientsIndependent prognostic valueSerum lactate dehydrogenasePrognostic index modelSpecific prognostic markersLarge cell transformationT cell clonesIIB disease
2013
A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study
Foss FM, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith MR, Komrokji R, Pendergrass K, Bolejack V. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leukemia & Lymphoma 2013, 54: 1373-1379. PMID: 23278639, DOI: 10.3109/10428194.2012.742521.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaDenileukin diftitoxT-cell lymphomaAdverse eventsOverall survivalFrequent treatment-related adverse eventsUntreated peripheral T-cell lymphomaMedian progression-free survivalMost frequent adverse eventsMulticenter phase II trialTreatment-related adverse eventsTreatment-related deathsFrequent adverse eventsMedian overall survivalPhase II studyPhase II trialProgression-free survivalOverall survival rateOverall response rateITT populationSafety populationII trialII studyMedian durationLarge trials
2012
Long‐term follow‐up and survival of cutaneous T‐cell lymphoma patients treated with extracorporeal photopheresis
Knobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Foss F, Kuzel T, Campbell K, Geskin L. Long‐term follow‐up and survival of cutaneous T‐cell lymphoma patients treated with extracorporeal photopheresis. Photodermatology Photoimmunology & Photomedicine 2012, 28: 250-257. PMID: 22971190, DOI: 10.1111/j.1600-0781.2012.00689.x.Peer-Reviewed Original ResearchConceptsDuration of responseOverall response rateExtracorporeal photopheresisOverall survivalSkin responseResponse rateImpact of ECPCutaneous T-cell lymphomaMedian overall survivalSurvival of patientsT-cell lymphomaLong-term treatmentECP initiationDurable responsesPivotal trialsPatientsCohortECP treatmentModern criteriaSurvivalTreatmentDiagnosisTrialsMonthsResponse
2011
Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sézary Syndrome: Correlation with O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins
Querfeld C, Rosen ST, Guitart J, Rademaker A, Pezen DS, Dolan ME, Baron J, Yarosh DB, Foss F, Kuzel TM. Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sézary Syndrome: Correlation with O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins. Clinical Cancer Research 2011, 17: 5748-5754. PMID: 21747120, PMCID: PMC3725971, DOI: 10.1158/1078-0432.ccr-11-0556.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAgedAged, 80 and overAntineoplastic Agents, AlkylatingDacarbazineDNA DamageDNA Mismatch RepairFemaleHumansMaleMiddle AgedMutL Protein Homolog 1MutS Homolog 2 ProteinMycosis FungoidesNuclear ProteinsO(6)-Methylguanine-DNA MethyltransferaseSezary SyndromeTemozolomideTreatment OutcomeConceptsMycosis fungoides/Sézary syndromeMulticenter phase II trialPhase II trialMF/SSMethylguanine-DNA methyltransferaseMutL homolog 1II trialSézary syndromeMedian disease-free survivalMismatch repair protein expressionGrade 3 thrombocytopeniaMedian overall survivalDisease-free survivalEfficacy of temozolomideRepair protein expressionProtein expression levelsOral derivativeComplete remissionConstitutional symptomsFrequent toxicitiesGastrointestinal symptomsHematologic toxicityPartial remissionClinical responseOverall survival
2002
A Phase II Trial of Daily Perillyl Alcohol in Patients with Advanced Ovarian Cancer: Eastern Cooperative Oncology Group Study E2E96
Bailey HH, Levy D, Harris LS, Schink JC, Foss F, Beatty P, Wadler S. A Phase II Trial of Daily Perillyl Alcohol in Patients with Advanced Ovarian Cancer: Eastern Cooperative Oncology Group Study E2E96. Gynecologic Oncology 2002, 85: 464-468. PMID: 12051875, DOI: 10.1006/gyno.2002.6647.Peer-Reviewed Original ResearchConceptsProgression-free rateAdvanced ovarian cancerOvarian cancerPerillyl alcoholMedian progression-free survivalPrior platinum-based therapyAdvanced ovarian carcinomaMedian overall survivalObjective response ratePhase II studyPhase II trialProgression-free survivalLDL cholesterol levelsPlatinum-based therapyGastrointestinal toxicityII trialPrimary endpointRecurrent diseaseUnacceptable toxicityII studyOverall survivalPartial responseHistoric controlsCholesterol levelsOvarian carcinoma